For richer charts and full features, open SpikePanel on desktop.
Graded daily on value B-, growth C+, profitability A-, momentum B. Sector-relative, identical for every user.
Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $KVUE are available with SpikePanel Pro.
Key events, in time order
Acquisition closed; KVUE removed from S&P 500 and delisted, brands absorbed into Kimberly-Clark
Revenue $3.89B up 3.2% YoY; adj EPS $0.29 beat estimates
Multiple sources continue coverage of acquisition progress and dividend appeal
Kimberly-Clark prepares EU remedies to advance $40B acquisition
Inflation, tariffs and FX pressure margins; revenue grows but profit metrics miss
Multiple Zacks reports cite pending deal and slow organic growth as key uncertainties.
Dividend hike confirmed by BusinessWire, with Zacks noting margin gains and stronger cash flow, reinforcing shareholder return signal.
Institutional buying plus options volatility signal heightens market attention
Federal appeals court revives hundreds of lawsuits against Kenvue and retailers alleging Tylenol causes autism and ADHD, sending cases back to lower courts.
None yet
None yet
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice